CS
AVXL icon

Credit Suisse’s Anavex Life Sciences AVXL Stock Holding History

Credit Suisse’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$502K Buy
98,689
+1,225
+1% +$6.89K ﹤0.01% 2637
2023
Q4 		$907K Buy
97,464
+260
+0.3% +$1.79K ﹤0.01% 2396
2023
Q3 		$637K Sell
97,204
-17,270
-15% -$137K ﹤0.01% 2556
2023
Q2 		$931K Buy
114,474
+25,311
+28% +$217K ﹤0.01% 2426
2023
Q1 		$764K Buy
89,163
+4,191
+5% +$41.8K ﹤0.01% 2483
2022
Q4 		$787K Buy
84,972
+18,248
+27% +$195K ﹤0.01% 2507
2022
Q3 		$689K Buy
66,724
+6,916
+12% +$73K ﹤0.01% 2588
2022
Q2 		$599K Buy
59,808
+5,899
+11% +$55.9K ﹤0.01% 2729
2022
Q1 		$663K Buy
53,909
+9,603
+22% +$118K ﹤0.01% 2814
2021
Q4 		$769K Buy
44,306
+657
+2% +$12.5K ﹤0.01% 3524
2021
Q3 		$784K Buy
43,649
+3,719
+9% +$74K ﹤0.01% 3521
2021
Q2 		$913K Buy
+39,930
New +$591K ﹤0.01% 3459
2021
Q1 		– Sell
-15,071
Closed -$81K – 4290
2020
Q4 		$81K Buy
+15,071
New +$79.4K ﹤0.01% 4201
2020
Q2 		– Sell
-10,900
Closed -$35K – 3951
2020
Q1 		$35K Buy
+10,900
New +$38K ﹤0.01% 3922
2019
Q2 		– Sell
-21,902
Closed -$67K – 4082
2019
Q1 		$67K Sell
21,902
-14,603
-40% -$34.9K ﹤0.01% 3883
2018
Q4 		$57K Sell
36,505
-2
-0% -$5 ﹤0.01% 3791
2018
Q3 		$100K Sell
36,507
-849
-2% -$2.4K ﹤0.01% 3719
2018
Q2 		$98K Sell
37,356
-13,144
-26% -$36.7K ﹤0.01% 3836
2018
Q1 		$140K Buy
50,500
+3,308
+7% +$9.35K ﹤0.01% 3756
2017
Q4 		$153K Sell
47,192
-14,824
-24% -$58.3K ﹤0.01% 3792
2017
Q3 		$257K Buy
62,016
+18,502
+43% +$82.2K ﹤0.01% 3817
2017
Q2 		$231K Buy
43,514
+3,022
+7% +$17.5K ﹤0.01% 3578
2017
Q1 		$233K Sell
40,492
-8,512
-17% -$44K ﹤0.01% 3590
2016
Q4 		$194K Sell
49,004
-16,933
-26% -$60.3K ﹤0.01% 3822
2016
Q3 		$239K Buy
65,937
+14,660
+29% +$61.7K ﹤0.01% 3747
2016
Q2 		$314K Sell
51,277
-51,650
-50% -$250K ﹤0.01% 3676
2016
Q1 		$505K Buy
102,927
+5,488
+6% +$24.1K ﹤0.01% 3228
2015
Q4 		$543K Buy
+97,439
New +$693K ﹤0.01% 3320

Other funds holding AVXL

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $1.74B AUM 32.48% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse's AVXL Position: Q1 2024 in Review

Credit Suisse increased its Anavex Life Sciences (AVXL) stake by 1.3% in Q1 2024, buying an estimated $6.89K and bringing the position to 98,689 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #2637.

Credit Suisse first reported a position in AVXL in Q4 2015 and has held it in 28 quarters since. The position peaked at $931K in Q2 2023. 147 funds tracked by Wall St. Rank hold AVXL as of Q1 2024.

  • Credit Suisse held 98,689 shares of Anavex Life Sciences worth $502K as of Q1 2024.
  • Credit Suisse bought 1,225 Anavex Life Sciences shares in Q1 2024, an estimated $6.89K.
  • Anavex Life Sciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2637 holding.
  • Credit Suisse first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 28 quarters since.
  • Credit Suisse's Anavex Life Sciences position peaked at $931K in Q2 2023.
  • 147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.